ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MXCT Maxcyte Inc

334.00
-1.00 (-0.30%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.30% 334.00 61,208 16:08:25
Bid Price Offer Price High Price Low Price Open Price
330.00 338.00 335.00 330.00 335.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics USD 41.29M USD -37.92M USD -0.3664 -11.49 346.74M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:13:05 O 24,328 337.00 GBX

Maxcyte (MXCT) Latest News

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
15/11/202418:26Maxcyte: Any molecule, any cell, any scale1,527
21/1/202214:00Anybody know what is going on?-
13/7/202111:48MaxCyte (MXCT) Right here, right now: catching the CAR-T wave5
23/11/202009:57CRISPR-

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:40:47337.0024,32881,985.36O
16:13:06336.007262,439.36O
16:07:39332.505,00016,625.00O
15:55:13340.0013.40O
15:40:53337.004,74715,997.39O

Maxcyte (MXCT) Top Chat Posts

Top Posts
Posted at 13/12/2024 08:20 by Maxcyte Daily Update
Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 335p.
Maxcyte currently has 103,504,571 shares in issue. The market capitalisation of Maxcyte is £435,754,244.
Maxcyte has a price to earnings ratio (PE ratio) of -11.49.
This morning MXCT shares opened at 335p
Posted at 15/11/2024 14:44 by sword77
So why is the share price so low right now? Quarter was good, beat estimates and raised guidance but share price went down the drain...

Can the likely delisting be that impactful?
Posted at 12/11/2024 11:57 by adamb1978
Thanks. Also need to remember that you don't know what point in teh quarter that treatment stated and how they're accounting for it.

If its a course of treatment spread over a period of time then they'd probably amortise the revenues over that period and in which you need to know when in Q3 started. They could have 1 day of that amortisation in Q3 or 90 days or more likely somewhere in between.

If they account for it as a one time sale then the price point clearly is lower. They might also need to hold back some revenue for post-treatment support etc.

My guess, given its royalty related, is that its the former accounting period, but Q4 should show us more clearly what the potential per patient is
Posted at 08/11/2024 11:13 by adamb1978
58,000 customers * $2.2m = $127.6bn market?

Justifies a few billion for them, and few tens of million p.a. for MXCT
Posted at 05/3/2024 08:59 by adamb1978
Not sure Dave. THe core revenue growth figure is underwhelming - new licenses are meant to tranlsate into incremental revenues...wonder whether:

- any licensees have terminated?
- any have asked for restructured/written off payments due to funding problems?
- MXCT have changed commercial structures?
Posted at 08/12/2023 18:32 by adamb1978
Very nice. Share price down 4% in NY!!
Posted at 08/12/2023 17:36 by lancasterbomber
Surprised share price went down not up
Posted at 27/9/2023 12:39 by adamb1978
Cash isn’t remotely an issue here. As the other poster said, they have boat loads of the stuff!

Question is whether their lead customer gets approval back from the regulators in a couple months time

The share price at the moment is effectively assuming that gets rejected. You can understand the price drifting down over recent months as such a big proportion of the newsflow for MXCT this year is the end-nov approval.

Therefore there’s big upside of the green light comes. If it doesn’t, I wouldn’t be surprised if the Board looks for a buyer and a huge MedTech type company sweeps them up
Posted at 23/9/2023 12:01 by adamb1978
74tom

Difficult with an offer would be valuation. Is that a price which (i) the Directors would recommend and (ii) someone would offer

As you say, the business is almost free (net of cash) so the premium would need to be huge, and could an acquiror get that through their board?

MXCT share price is really in a holding pattern until the regulatory approval is back on Crispr...not long to go now though!

Adam
Posted at 23/9/2023 07:04 by 74tom
Looking interesting here from a valuation standpoint given the upcoming catalysts.

At the start of Covid MXCT raised capital at £1.31, post that raise they had ~£35m cash & 76.5m shares in issue, giving a post raise cap of £100m & EV of £65m / $80m.

At last nights $3.12 close on NASDAQ the market cap was down to $336m with cash likely to be ~$210m ($5m quarterly burn net of interest income). So EV of $126m.

Therefore, if EV declines by another $46m, the company is as fundamentally cheap as at the start of Covid, but with 4x as much cash. Share price wise that equates to around $2.80 / £2.30.

Giving the world class IP & industry standing, surely there is a real risk of a takeover attempt?
Posted at 15/3/2023 09:33 by adamb1978
Results are this evening, though we already know the 2022 top line figure and their initial guidance for 2023.

MXCT share price has been weak recently however if you look at various other healthcare companies, most of them have come off too.
Maxcyte share price data is direct from the London Stock Exchange

Maxcyte Frequently Asked Questions (FAQ)

What is the current Maxcyte share price?
The current share price of Maxcyte is 334p.
How many Maxcyte shares are in issue?
Maxcyte has 103,504,571 shares in issue.
What is the market cap of Maxcyte?
The market capitalisation of Maxcyte is GBP 346.74 M.
What is the 1 year trading range for Maxcyte share price?
Maxcyte has traded in the range of 256.00p to 420.00p during the past year.
What is the PE ratio of Maxcyte?
The price to earnings ratio of Maxcyte is -11.49.
What is the cash to sales ratio of Maxcyte?
The cash to sales ratio of Maxcyte is 10.55.
What is the reporting currency for Maxcyte?
Maxcyte reports financial results in USD.
What is the latest annual turnover for Maxcyte?
The latest annual turnover of Maxcyte is USD 41.29M.
What is the latest annual profit for Maxcyte?
The latest annual profit of Maxcyte is USD -37.92M.
What is the registered address of Maxcyte?
The registered address for Maxcyte is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808.
What is the Maxcyte website address?
The website address for Maxcyte is www.maxcyte.com.
Which industry sector does Maxcyte operate in?
Maxcyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector.